Clinical Implications of ‘Low’ HER2 Expression: 2023 Best of Breast Conference
Dr Sunil Badve, MD, FRCPath from Emory University comments on the treatment implications of lower HER2 expression levels in breast cancer: Evolving clinical paradigms for ‘HER2 positive’ disease, re-defining ‘triple negative’ status, and a changing landscape of targetable mutations and effective treatments.
Related Resources